布鲁克戴尔大学医院内科医生同行评审位置：
研究吸入形式伊维菌素的COVID-19
现在，来自纽约布鲁克林布鲁克布鲁克大学医院医学中心的一组医生
他们的手稿最近在同行评议期刊Cureus上发表。
研究小组提醒所有人，随着SARS-CoV-2（COVID-91背后的病毒）的到来，人们对安全有效的治疗方法和疫苗的需求激增，
并展现了诺言
通过莫纳什大学的实验，医生建议研究应研究伊维菌素的吸入形式，其浓度应足以确保有效抵抗SARS-CoV-2。
Although not documented, which isn’t totally true as TrialSite has chronicled several observational studies, and even one randomized controlled trial, the authors choose to ignore these except for the ICON study in Broward County.
Regardless, they suggest that the anthelminthic drug may have broad-spectrum antiviral properties, which could make it effective against viral infections such as SARS-CoV-2.
They emphasize a need to study ivermectin in an inhaled form and although TrialSite suggests these physicians could have dug a little deeper into studies in the developing world such as in
- Bangladesh,
- Argentina or for that matter,
- Egypt and Iraq,
they are on the right side of history here suggesting research proceed.